Jesús Zoco

762 total citations
7 papers, 344 citations indexed

About

Jesús Zoco is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jesús Zoco has authored 7 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in Jesús Zoco's work include Cancer Immunotherapy and Biomarkers (6 papers), Renal cell carcinoma treatment (5 papers) and Cancer Genomics and Diagnostics (2 papers). Jesús Zoco is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Renal cell carcinoma treatment (5 papers) and Cancer Genomics and Diagnostics (2 papers). Jesús Zoco collaborates with scholars based in United States, United Kingdom and Germany. Jesús Zoco's co-authors include Nicola Fattorelli, Evgenia Salta, Annerieke Sierksma, Luc Buée, Renzo Mancuso, Bart De Strooper, Mark Fiers, David Blum, Ashley Lu and Nicola Thrupp and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and EMBO Molecular Medicine.

In The Last Decade

Jesús Zoco

7 papers receiving 338 citations

Peers

Jesús Zoco
Rui Ji China
Yuki Toda Japan
Caroline I. Schnegg United States
Nirma D. Perera Australia
Min Chao China
Jacob Sterling United States
Rui Ji China
Jesús Zoco
Citations per year, relative to Jesús Zoco Jesús Zoco (= 1×) peers Rui Ji

Countries citing papers authored by Jesús Zoco

Since Specialization
Citations

This map shows the geographic impact of Jesús Zoco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesús Zoco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesús Zoco more than expected).

Fields of papers citing papers by Jesús Zoco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesús Zoco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesús Zoco. The network helps show where Jesús Zoco may publish in the future.

Co-authorship network of co-authors of Jesús Zoco

This figure shows the co-authorship network connecting the top 25 collaborators of Jesús Zoco. A scholar is included among the top collaborators of Jesús Zoco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesús Zoco. Jesús Zoco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Tykodi, Scott S., Lucio Gordan, Robert Alter, et al.. (2022). Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. Journal for ImmunoTherapy of Cancer. 10(2). e003844–e003844. 85 indexed citations
2.
Tykodi, Scott S., Lucio Gordan, Robert Alter, et al.. (2021). Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.. Journal of Clinical Oncology. 39(6_suppl). 309–309. 13 indexed citations
3.
Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2021). Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. Journal of Clinical Oncology. 39(15_suppl). 4515–4515. 5 indexed citations
4.
Hutson, Thomas E., Bradley Curtis Carthon, Jeffrey T. Yorio, et al.. (2021). Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.. Journal of Clinical Oncology. 39(6_suppl). 315–315. 2 indexed citations
5.
Lebbé, Célèste, Nicolás Meyer, Laurent Mortier, et al.. (2021). Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. Journal of Clinical Oncology. 39(15_suppl). 9516–9516. 18 indexed citations
6.
Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2021). Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 128(5). 966–974. 31 indexed citations
7.
Sierksma, Annerieke, Ashley Lu, Renzo Mancuso, et al.. (2020). Novel Alzheimer risk genes determine the microglia response to amyloid‐β but not to TAU pathology. EMBO Molecular Medicine. 12(3). e10606–e10606. 190 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026